Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 6 , Pages 693-702 , December 2009

Immune reconstitution syndrome and the thyroid

References 

  1. Weetman AP. Graves' disease. The New England Journal of Medicine. 2000;26(343):1236–1248
  2. Zeitlin AA, Heward JM, Newby PR, et al. Analysis of HLA class II genes in Hashimoto's thyroiditis reveals differences compared to Graves' disease. Genes and Immunity. 2008;9:358–363
  3. Prummel MF, Strieder T, Wiersinga WM. The environment and autoimmune thyroid diseases. European Journal of Endocrinology. 2004;150:605–618
  4. Burt RK, Slavin S, Burns WH, et al. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. Blood. 2002;99:768–784
  5. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplantation. 1998;22:873–881
  6. Aldouri MA, Ruggier R, Epstein O, et al. Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia. British Journal of Haematology. 1990;74:118–119
  7. Karthaus M, Gabrysiak T, Brabant G, et al. Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells. Bone Marrow Transplantation. 1997;20:697–699
  8. Berisso GA, van Lint MT, Bacigalupo A, et al. Adoptive autoimmune hy perthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease. Bone Marrow Transplantation. 1999;23:1091–1092
  9. Takeshita A, Shinjo K, Ohno R. Graves' disease after bone marrow transplantation. Annals of Internal Medicine. 1999;131:157
  10. Yamamori I, Kanie T, Maeda N, et al. Appearance of thyroid stimulating and blocking immunoglobulins after bone marrow transplantation: presentation of two contrasting cases. Endocrine Journal. 2004;51:439–443
  11. Hsiao LT, Liu JH, Yen CC, et al. Relapse of Graves' disease after successful allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2001;28:1151–1153
  12. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature. 1988;332:323–327
  13. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119:225–237
  14. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology. 2005;10:79–93
  15. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 1994;344:298–301
  16. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691–1695
  17. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. Journal of Neurology. 2008;255:231–238
  18. CAMMS223 Trial Investigators , Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. The New England Journal of Medicine. 2008;359:1786–1801
  19. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Annals of the Rheumatic Diseases. 2008;67:1322–1327
  20. Thachil J, Jadhav V, Gautam M, et al. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution. British Journal of Haematology. 2007;138:559–560
  21. Lorenzi AR, Clarke AM, Wooldridge T, et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis and Rheumatism. 2008;58:370–375
  22. Kirk AD, Hale DA, Swanson SJ, et al. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. American Journal of Transplantation. 2006;6:1084–1085
  23. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. The New England Journal of Medicine. 2008;359:768–769
  24. Broadley SA, Deans J, Sawcer SJ, et al. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain. 2000;123:1102–1111
  25. Niederwieser G, Buchinger W, Bonelli RM, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. Journal of Neurology. 2003;250:672–675
  26. Hafler JP, Maier LM, Cooper JD, et al., The International Multiple Sclerosis Genetics Consortium (IMSGC)  CD226 Gly307Ser association with multiple autoimmune diseases. Genes and Immunity. 2009;10:5–10
  27. Monzani F, Caraccio N, Meucci G, et al. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. European Journal of Endocrinology. 1999;141:325–331
  28. Monzani F, Caraccio N, Casolaro A, et al. Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful?. Neurology. 2000;55:549–552
  29. Durelli L, Oggero A, Verdun E, et al. Betaferon Safety Trial (BEST) Study Group. Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study. Journal of the Neurological Sciences. 2001;193:17–22
  30. Caraccio N, Dardano A, Manfredonia F, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4133–4137
  31. Polman CH, Kappos L, Dahlke F, et al. European Study Group on Interferon Beta-1b in SPMS. Interferon beta-1b treatment does not induce autoantibodies. Neurology. 2005;64:996–1000
  32. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. RNF Study Group. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clinical Therapeutics. 2007;29:1128–1145
  33. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112–116
  34. Hoffmann CJ, Brown TT. Thyroid function abnormalities in HIV-infected patients. Clinical Infectious Diseases. 2007;45:488–494
  35. Madge S, Smith CJ, Lampe FC, et al. No association between HIV disease and its treatment and thyroid function. HIV Medicine. 2007;8:22–27
  36. Madeddu G, Spanu A, Chessa F, et al. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. Clinical Endocrinology. 2006;64:375–383
  37. Gilquin J, Viard JP, Jubault V, et al. Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet. 1998;352:1907–1908
  38. Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clinics in Endocrinology and Metabolism. 2000;85:4254–4257
  39. Sereti I, Sarlis NJ, Arioglu E, et al. Alopecia universalis and Graves' disease in the setting of immune restoration after highly active antiretroviral therapy. AIDS. 2001;15:138–140
  40. French MA, Lewin SR, Dykstra C, et al. Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Research and Human Retroviruses. 2004;20:157–162
  41. Chen F, Day SL, Metcalfe RA, et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine. 2005;84:98–106
  42. Knysz B, Bolanowski M, Klimczak M, et al. Graves' disease as an immune reconstitution syndrome in an HIV-1-positive patient commencing effective antiretroviral therapy: case report and literature review. Viral Immunology. 2006;19:102–107
  43. Brown JD, Kangwanprasert M, Tice A, et al. Thyrotoxic periodic paralysis in a Polynesian male following highly active antiretroviral therapy for HIV infection. Hawaii Medical Journal. 2007;66(60):62–63
  44. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Seminars in Arthritis and Rheumatism. 2005;35:166–174
  45. O'Leary JG, Zachary K, Misdraji J, et al. De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clinical Infectious Diseases. 2008;46:e12–e14
  46. Price P, Mathiot N, Krueger R, et al. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. Journal of Clinical Virology. 2001;22:279–287
  47. Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. The Journal of Infection. 2005;51:e289–e297
  48. Gleeson PA, Toh BH, van Driel IR. Organ-specific autoimmunity induced by lymphopenia. Immunological Reviews. 1996;149:97–125
  49. Sakaguchi S, Sakaguchi N. Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. Journal of Immunology. 1989;142:471–480
  50. Schwartz RH. Natural regulatory T cells and self-tolerance. Nature Immunology. 2005;6:327–330
  51. Clatworthy MR, Wallin EF, Jayne DR. More on anti-glomerular basement membrane disease after alemtuzumab. author reply The New England Journal of Medicine. 2008;359:2502
  52. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. European Journal of Immunology. 2005;35:3332–3342
  53. Hagen KA, Moses CT, Drasler EF, et al. A role for CD28 in lymphopenia-induced proliferation of CD4 T cells. Journal of Immunology. 2004;173:3909–3915
  54. Krupica T, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: a two-hit model. Clinical Immunology. 2006;120:121–128
  55. Gallegos AM, Bevan MJ. Driven to autoimmunity: the nod mouse. Cell. 2004;117:149–151

PII: S1521-690X(09)00079-7

doi: 10.1016/j.beem.2009.07.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 6 , Pages 693-702 , December 2009

Article Tools